The gut microbiota is a collection of bacteria, archaea, fungi, protozoa, and viruses that colonize the intestines, with a number reaching tens of trillions. The gut microbiota, host, and external environment are in a dynamic balance. Evidence has long shown the protective role of the gut microbiota in health. In recent years, thanks to the development and progress of various technologies, people have gained a deeper understanding and insight into the complex interactions between the gut microbiota and human health and disease.
In recent years, the approval for live biologics on the market and the widespread use of probiotic products have marked the entry of the gut microbiota industry into a period of rapid development. As of April 2025, there are nearly four hundred ongoing gut microbiota drug pipelines globally, developing rapidly. At the same time, the potential value of probiotics and second-generation probiotics has been continuously revealed in recent years, becoming a hot topic of interest in academia and industry.
This report aims to conduct an in-depth analysis of the gut microbiota industry, exploring the industry value from various aspects such as industry overview, development models, and competitive landscape, investigating the driving factors behind industry development, uncovering the huge potential for industry development, and tracking the future development trends of the gut microbiota industry.
